Abstract:Objective: To investigate the curative effect of local application of CpG-oligodeoxynucleotide (CpG-ODN) combined with 4-1BB monoclonal antibody in hepatoma-bearing mice, and to evaluate the effect of 4-1BB monoclonal antibody on CpG-ODN immunotherapy. Methods: H22 single cell suspension was injected subcutaneously into the axilla and four limbs of the BALB/c male mice to establish a tumor-bearing mice model. After 7 days, 30 mice with corresponding tumor-bearing volume were screened and randomly divided into model control group, CpG group and CpG+4-1BB group, and the drug was injected into the tumors of left lower extremity. The same batch of normal mice was selected as normal control group. Survival of mice was recorded. Tumor-bearing volume and organ index were calculated. Serum levels of interleukin (IL) - 12 and interferon (IFN) gamma and spleen CD8(+)T lymphocyte ratio were measured. The measurement data were analyzed by analysis of variance. The survival rate of each group of mice was analyzed by log-rank test. Results: Mice in the model control group with tumor-bearing volume had a sustained growth before the execution. CpG group and the CpG+4-1BB group [(976.08 ± 29.55) mm(3), (47.25 ± 0.93) mm(3))] tumor-bearing volume was decreased than model group [(1 336.52 ± 39.40) mm3] (F = 5 329.273, P < 0.05). CpG+4-1BB group distant tumor-bearing volume [(611.83 ± 113.02) mm3] was decreased than model group and CpG group [(1 406.62 ± 51.09) mm(3), (1 380.01 ± 51.44) mm3] (F = 247.160, P < 0.05), but there was no significant difference between the CpG group and the model group (P > 0.05). Serum IL-12 concentration (23.90 ± 2.33 pg/ml), IFN-γ concentration (103.02 ± 6.10 pg/ml) and spleen CD8(+)T cell ratio (4.54 ± 0.62%) in the model group were lower than those in the normal group (P < 0.05). Serum IL-12 concentration in CpG group and CpG+4-1BB group (29.21 ± 2.23 pg/ml, 37.04 ± 1.49 pg/ml), IFN-γ concentration (116.12 ± 4.08 pg/ml, 138.65 ± 1.72 pg/ml), CD8(+)T cell ratio (6.65 ± 0.64%, 12.73 ± 0.88%) were higher than the model group, while CpG+4-1BB group was higher than the CpG group (P < 0.05). The survival rate of CpG+4-1BB group was higher than that of model group and CpG group (χ(2) = 25.544, P < 0.05), but there was no significant difference between CpG group and model group (P > 0.05). There was no significant difference in organ index between the four groups (P > 0.05). Conclusion: 4-1BB monoclonal antibody combined with CpG-ODN therapy can shrink hepatoma-bearing capacity, inhibit the growth of distant tumors and significantly prolong the survival time of mice.

Effects of the Monoclonal Antibody Against the Provocative Type of Human 4-1BB on the Biological Characteristics of the Monocytic Leukemia Cell Line SHI-1

[Effects of Imatinib Mesylate on the Development of Dendritic Cells Derived from Bone Marrow Mononuclear Cells of Patients with Chronic Myeloid Leukemia].

Establishment of Human Acute Monocytic Leukemia Model in Severe Combined Immunodeficient (SCID) Mice and the Analysis of Pathological Changes

Preparation of a functional monoclonal antibody against human 4-1BBL molecule and analysis of its biological characteristics

Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation

Proliferation and Cytokine Secretion of Monocytes Stimulated by Reverse Signaling of 4-1BBL

Preparation of Anti-Human 4-1BB Monoclonal Antibody and Analysis of Its Biological Functions

[Establishment of the Human Acute Promyelocytic Leukemia Pathological Model in the SCID Beige Mice by Using NB4 Cell Line].

A Functional Anti-Human 4-1bb Ligand Monoclonal Antibody That Enhances Proliferation Of Monocytes By Reverse Signaling Of 4-1bbl

Experimental Study on Hematopoietic Reconstruction Effects of Peripheral Blood Stem Cells Mobilized by Anti-Cd49d Monoclonal Antibody Plus Rhg-Csf in Mice

[Development of HPV16 Positive Cervical Cancer Model in the Hu-Pbl-scid Mouse and Its Immunological Features].

[Transgenic 4-1-BB ligand therapy induces tumor specific immune response in oral squamous cell carcinoma]

Effects of 4-1BB signaling on the biological function of murine dendritic cells.

Study on the Effect of Anti-Leukemia in C57BL/6 Mice That Receive Immune Reconstitution

[Therapeutic Effect of Agonistic CD40 Monoclonal Antibody Combined with CTL on Hu-Scid Mouse B Lymphoma Model].

RNA Interfering of CXCR4 Inhibits the Adhesion, Invasion, and Tumorigenicity of Acute Monocytic Leukemic Cells in Vivo.

Antitumor efficacy of bispecific antibody mAb04-MICA to human leukemia cell K562 in vitro and in vivo

Preparation of anti-human 4-1BB monoclonal antibody and characterization of its biological activities]

[Study of local application of CpG-oligodeoxynucleotide combined with 4-1BB monoclonal antibody to treat hepatoma- bearing mice]

[Cloning, Expression and Antitumor Effect of Mouse Costimulatory Molecule 4-1BBL].

Inhibition of allogeneic CD3AK cells on human renal cell carcinoma xenografts in SCID mice